NCT07867795Not yet recruiting

Effects of the EatWelLog App on Enhancing Diet Management for Older Adults With Sarcopenic Obesity

Effects of the EatWelLog App on Enhancing Daily Diet Management for Community-dwelling Older Adults With Sarcopenic Obesity: A Randomized Controlled Trial (RCT)

Source: ClinicalTrials.gov · Last updated 9 Oct 2026

Brief summary (registry, in English)

Background: Sarcopenic obesity (SO) affects 10% of older adults increased to 23% of those 75+, raising health risks and health cost. Objectives: We will evaluate the effects of the EatWelLog App-based intervention on SO status (primary outcome), and nutritional and exercise parameters (secondary outcomes) by enhancing self-management and sustaining diet adherence among the m-Health group using the App versus the control group. Following verification of the intervention's effectiveness, we will analyse its cost-effectiveness. Design and subjects: Randomized controlled trial with 212 older people with SO. Interventions: The m-Health group will receive an 8-week supervised nutrition and exercise programme, incorporating the EatWelLog App for dietary management during and after the supervised programme. The control group will receive the same programme without the App. Main outcome measures and analysis: The primary outcome is SO status evaluated using handgrip strength, muscle mass, body fat mass, and physical performance. Secondary outcomes include nutritional status, quality of life and exercise adherence. The App intervention's costeffectiveness will be analysed. Expected results: The m-Health group should demonstrate greater, more sustained improvements in SO and secondary outcomes compared to the control group at Week 8, and at the 3-, 6-, 9-, and 12-month follow-ups. Clinical significance: The EatWelLog App could provide customized support, enhance dietary adherence, and improve long-term outcomes, offering a novel, economical approach to SO management.

Status (registry): Not yet recruiting
Study type: Interventional
Enrollment: 212 (estimated)
First submitted: 5 Oct 2026
Start date: Oct 2026
Primary completion date: Mar 2029
Lead sponsor: The Hong Kong Polytechnic University
Diseases: Obesity
NCT number: NCT07867795

What you commit to

Study type: Interventional
Planned participants: 212
From Oct 2026 to the primary completion date, Mar 2029
1 site in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

Taking medications that may influence eating behaviour, digestion, or metabolism (such as weight loss medication);
Having any medical implant device such as a pacemaker, because low-level currents will flow through the body when doing the bioelectric impedance analysis (BIA by InBody S10, Korea), which may cause the device to malfunction.

Other illness

With any form of disease or condition that might affect food intake and digestion (such as severe heart or lung diseases, renal diseases, diabetes, cancer, or autoimmune diseases);
With alcohol use disorder as defined by DSM-5, potentially hindering dietary behaviour changes; and

Other

Have a Functional Ambulatory Classification (FAC) score of \<7, indicating impaired mobility to participate in exercise training.

Who the study is looking for

Community-dwelling older people aged \> 50 years;
Meeting the diagnostic criteria of sarcopenia according to the Asian Sarcopenia Working Group (ASWG) which include:
Sarcopenia refers to the fulfillment both of the following criteria: For participants aged 50-64: low handgrip strength \< 34 kg for men and \< 20 kg for women, low muscle quality as reflected by low appendicular skeletal muscle mass (ASM) /height squared \< 7.6 kg/m2 for men and \<5.7 kg/m2 for women. For participants aged 65 or above: handgrip strength \<28kg (men) and \<18 kg (women); appendicular skeletal muscle mass (ASM)/ height2 \<7 kg/m2 (men) and \<5.7 kg/m2 (women).
Obesity refers to the fulfillment of one of the following criteria: Body Mass Index (BMI) ≥ 25kg/m2 or waist circumference ≥ 90 cm in men and ≥ 80 cm in women, or percentage of body fat \> 30%.
Able to communicate, read, and write in Chinese without significant hearing and vision problems to ensure that our instructions are understood; and • Own a smartphone, and able to access the internet at home or elsewhere.

Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
The Hong Kong Polytechnic University Coordinator of this site? Confirm its status	Hong Kong	Hong Kong SAR China	Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.